Notice: This company has been marked as potentially delisted and may not be actively trading. Vaccitech (VACC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesInsider TradesOwnershipTrends VACC vs. SAVA, IFRX, PBYI, APLT, MCRB, NBTX, IVA, RPTX, GALT, and LPTXShould you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Cassava Sciences (SAVA), InflaRx (IFRX), Puma Biotechnology (PBYI), Applied Therapeutics (APLT), Seres Therapeutics (MCRB), Nanobiotix (NBTX), Inventiva (IVA), Repare Therapeutics (RPTX), Galectin Therapeutics (GALT), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical preparations" industry. Vaccitech vs. Cassava Sciences InflaRx Puma Biotechnology Applied Therapeutics Seres Therapeutics Nanobiotix Inventiva Repare Therapeutics Galectin Therapeutics Leap Therapeutics Vaccitech (NASDAQ:VACC) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk. Which has preferable earnings & valuation, VACC or SAVA? Vaccitech has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaccitech$13.42M2.80$5.34M-$1.43-0.68Cassava SciencesN/AN/A-$97.22M-$1.38-1.85 Does the MarketBeat Community believe in VACC or SAVA? Cassava Sciences received 81 more outperform votes than Vaccitech when rated by MarketBeat users. However, 70.83% of users gave Vaccitech an outperform vote while only 65.33% of users gave Cassava Sciences an outperform vote. CompanyUnderperformOutperformVaccitechOutperform Votes1770.83% Underperform Votes729.17% Cassava SciencesOutperform Votes9865.33% Underperform Votes5234.67% Which has more risk and volatility, VACC or SAVA? Vaccitech has a beta of -0.4, meaning that its stock price is 140% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.86, meaning that its stock price is 186% less volatile than the S&P 500. Do analysts rate VACC or SAVA? Cassava Sciences has a consensus price target of $111.50, indicating a potential upside of 4,272.55%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Vaccitech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccitech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is VACC or SAVA more profitable? Cassava Sciences has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Vaccitech-409.18% -23.41% -20.85% Cassava Sciences N/A -88.05%-64.98% Does the media favor VACC or SAVA? In the previous week, Cassava Sciences had 22 more articles in the media than Vaccitech. MarketBeat recorded 22 mentions for Cassava Sciences and 0 mentions for Vaccitech. Cassava Sciences' average media sentiment score of 0.13 beat Vaccitech's score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Overall Sentiment Vaccitech Neutral Cassava Sciences Neutral Do institutionals & insiders believe in VACC or SAVA? 26.1% of Vaccitech shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 6.0% of Vaccitech shares are owned by company insiders. Comparatively, 12.2% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryCassava Sciences beats Vaccitech on 10 of the 17 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Vaccitech News Delivered to You Automatically Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VACC vs. The Competition Export to ExcelMetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.55M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-0.6810.75135.1817.54Price / Sales2.80287.861,228.03140.34Price / Cash19.3056.6540.6537.95Price / Book0.155.394.884.92Net Income$5.34M$152.04M$118.97M$225.78M Vaccitech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VACCVaccitechN/A$0.92-5.1%N/A-70.1%$35.58M$13.42M-0.6533Gap UpSAVACassava Sciences4.5535 of 5 stars$3.22+5.2%$111.50+3,362.7%-87.9%$154.91MN/A0.0030News CoverageHigh Trading VolumeIFRXInflaRx2.7743 of 5 stars$2.60-0.8%$8.00+207.7%+69.5%$153.10M$168,498.00-2.5460Positive NewsGap DownHigh Trading VolumePBYIPuma Biotechnology4.1293 of 5 stars$3.00-3.8%$7.00+133.3%-25.5%$147.27M$235.60M6.50185Positive NewsAPLTApplied Therapeutics4.5162 of 5 stars$1.24-3.5%$6.60+434.4%-62.8%$143.71M$9.99M0.0030Gap DownHigh Trading VolumeMCRBSeres Therapeutics3.5771 of 5 stars$0.84+1.6%$5.08+507.9%-11.3%$142.77M$126.32M0.00233News CoverageHigh Trading VolumeNBTXNanobiotix1.6685 of 5 stars$3.00flat$12.00+300.0%-43.3%$141.39M$39.18M0.00100News CoverageGap UpHigh Trading VolumeIVAInventiva3.2386 of 5 stars$2.63-0.8%$13.25+403.8%-45.2%$138.02M$18.91M0.00100Gap DownRPTXRepare Therapeutics3.4652 of 5 stars$3.10-1.6%$10.00+222.6%-78.4%$131.78M$66.52M-1.58180GALTGalectin Therapeutics2.3649 of 5 stars$1.99-2.9%$11.00+452.8%+32.5%$124.89MN/A-2.489Options VolumeHigh Trading VolumeLPTXLeap Therapeutics2.172 of 5 stars$3.16-3.4%$7.50+137.3%+2.6%$121.09M$1.50M0.0040Positive News Related Companies and Tools Related Companies Cassava Sciences Competitors InflaRx Competitors Puma Biotechnology Competitors Applied Therapeutics Competitors Seres Therapeutics Competitors Nanobiotix Competitors Inventiva Competitors Repare Therapeutics Competitors Galectin Therapeutics Competitors Leap Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VACC) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
